Tolerx, Inc.: Cambridge, Massachusetts (ots/PRNewswire) - Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell ...

presseportal.de